Corbus Pharmaceuticals Earnings Reports

Corbus Pharmaceuticals reported a net loss of $17.0 million for the first quarter of 2025, primarily driven by increased clinical development expenses. The company made progress in its pipeline, presenting promising data for CRB-701 and initiating a Phase 1 study for CRB-913, while maintaining a cash position expected to fund operations through Q2 2027.

Corbus Pharmaceuticals reported a net loss of $13.8 million, or $1.15 per diluted share, for the three months ended September 30, 2024. As of September 30, 2024, the Company had $159.4 million in cash, cash equivalents and investments on hand, which is expected to fund operations through Q3 2027.

Corbus Pharmaceuticals reported a net loss of $10.0 million for the second quarter of 2024. The company's cash, cash equivalents, and investments totaled $147 million as of June 30, 2024, which, along with additional net proceeds, is expected to fund operations through Q3 2027.

Corbus Pharmaceuticals reported a net loss of $6.9 million for Q1 2024. The company dosed the first patient in the U.S. Phase 1 clinical trial of CRB-701 and expects to dose the first patient in the CRB-913 Phase 1 study in Q1 2025. They also raised $116 million in capital, extending their cash runway through Q1 2027.

Corbus Pharmaceuticals reported a net loss of $8.0 million for the fourth quarter of 2023. The company's operating expenses decreased by $0.7 million compared to the same period in the prior year. The company had $20.9 million of cash, cash equivalents, and investments on December 31, 2023, and $127 million on February 2, 2024 after raising $116 million of capital in 2024.

Corbus Pharmaceuticals reported a net loss of $10.1 million for the third quarter of 2023, compared to a net loss of $8.8 million for the same period in 2022. Operating expenses increased to $9.5 million, primarily due to manufacturing costs for CRB-601 clinical trial material.

Corbus Pharmaceuticals reported a net loss of $8.8 million for the second quarter of 2023. Substantial progress was made advancing CRB-701. The company's cash, cash equivalents and investments on hand are expected to fund operations through the second quarter of 2024.

Corbus Pharmaceuticals reported a net loss of $17.7 million for the first quarter of 2023. The company's operating expenses increased due to the upfront payment for the CSPC License Agreement and a development milestone under the USCF License Agreement. As of March 31, 2023, the company's cash and investments are expected to fund operations through the second quarter of 2024.

Corbus Pharmaceuticals reported a net loss of $10.9 million for the fourth quarter of 2022. The company's cash and investments on hand are expected to fund operations through the second quarter of 2024.

Corbus Pharmaceuticals reported a net loss of approximately $8.8 million, or a net loss per diluted share of $0.07, for the three months ended September 30, 2022. The company's cash and investments on hand of $67 million is expected to fund operations through the second quarter of 2024.

Corbus Pharmaceuticals reported a net loss of $13.2 million for the second quarter of 2022. The company's cash and investments on hand of $74 million are expected to fund operations into the first quarter of 2024.

Corbus Pharmaceuticals reported a net loss of $9.4 million for the first quarter of 2022. The company's cash and investments on hand of $86.8 million are expected to fund operations into the first quarter of 2024.

Corbus Pharmaceuticals reported a net loss of approximately $10.3 million for the three months ended December 31, 2021. The company's cash and investments on hand of $98.3 million is expected to fund operations into the first quarter of 2024.

Corbus Pharmaceuticals reported a net loss of $2.2 million for Q3 2021, with revenue from awards and licenses at $97,000. Operating expenses decreased by $21.2 million compared to the same period last year. The company's cash and investments on hand of $108 million are expected to fund operations into the first quarter of 2024.

Corbus Pharmaceuticals reported revenue from awards and licenses of $137,000 for the second quarter of 2021. Operating expenses decreased by $21.6 million to $16.8 million. The company reported a net loss of $17.1 million, or a net loss per diluted share of $0.15.

Corbus Pharmaceuticals reported revenue of $648,000 and a net loss of $16.1 million for the first quarter of 2021. The company's cash, cash equivalents, and investments were $125 million as of March 31, 2021, which is expected to fund operations into the first quarter of 2024.

Corbus Pharmaceuticals reported Q4 2020 financial results, with revenue from awards and licenses at $700,000, operating expenses at $21.5 million, and a net loss of $8.6 million. The company had approximately $85.4 million in cash and cash equivalents at the end of the year and expects to fund operations into Q1 2024 with $127M of cash on hand as of March 15, 2021.

Corbus Pharmaceuticals reported a net loss of $34.9 million for the third quarter of 2020. The company is focusing on its lenabasum dermatomyositis program and preclinical pipeline, with expectations to extend its cash runway through cost savings.

Corbus Pharmaceuticals reported a net loss of $38.1 million for Q2 2020, with revenue decreasing by $28.8 million to $0.3 million due to the absence of a licensing payment from Kaken Pharmaceuticals that was present in Q2 2019. Operating expenses increased by $11.0 million to $38.4 million. The company expects its cash and cash equivalents on hand of approximately $101 million at July 28, 2020 to fund operations into the third quarter of 2021.

Corbus Pharmaceuticals reported a net loss of $29.657 million, or $0.43 per diluted share, for the quarter ended March 31, 2020. Revenue decreased by $0.1 million to $1.8 million. The company completed a public offering in February 2020 that raised approximately $43 million in net proceeds and ended the quarter with approximately $46.6 million in cash and cash equivalents.

Corbus Pharmaceuticals reported revenue of $2.6 million and a net loss of $26.6 million for the fourth quarter ended December 31, 2019. The company's cash and cash equivalents were $31.7 million at the end of the quarter.